The common TEAEs that occurred in this study were generally consistent with those listed on the label of denosumab, such as hypocalcemia, hypophosphatemia, increased PTH levels, and arthralgia (Amgen, 2021). This evidence concerns the gene PTH and Hypocalcemia.